Posts by Ibiayi Dagogo-Jack, MD
-
Review: Managing Lung Cancer in Patients With Interstitial Lung Disease
Massachusetts General Hospital researchers recently summarized evidence about the risk of lung cancer in patients with interstitial lung disease (ILD), considerations for diagnosis and treatment of lung cancer in that population, and monitoring for ILD progression during lung cancer treatment.
-
MET Alterations Are a Recurring Resistance Mechanism in ALK-Positive Lung Cancer
Massachusetts General Hospital Cancer Center researchers find that ALK/MET combination therapy is a rational approach to treatment of ALK-positive non-small-cell lung cancer.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
